Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer.

Grevel J, Jentsch G, Austin R, Prins NH, Lettieri J, Mitchell D, Huang F, Brose MS, Schlumberger M, Meinhardt G, Peña CEA, Ploeger BA.

Clin Transl Sci. 2019 Mar 28. doi: 10.1111/cts.12634. [Epub ahead of print]

PMID:
30920122
2.

Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous Moxifloxacin in Pediatric Patients: Dose Optimization in a Phase 1 Study.

Stass H, Lettieri J, Vanevski KM, Willmann S, James LP, Sullivan JE, Arrieta AC, Bradley JS.

J Clin Pharmacol. 2019 May;59(5):654-667. doi: 10.1002/jcph.1358. Epub 2019 Jan 25.

PMID:
30681729
3.

Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.

Marmé F, Gomez-Roca C, Graudenz K, Huang F, Lettieri J, Peña C, Trnkova ZJ, Eucker J.

Cancer Chemother Pharmacol. 2018 Apr;81(4):727-737. doi: 10.1007/s00280-018-3540-9. Epub 2018 Feb 21.

PMID:
29468456
4.

Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.

Gerisch M, Hafner FT, Lang D, Radtke M, Diefenbach K, Cleton A, Lettieri J.

Cancer Chemother Pharmacol. 2018 Jan;81(1):195-206. doi: 10.1007/s00280-017-3480-9. Epub 2017 Nov 29.

5.

No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects.

Huang F, Ajavon A, Huang E, Lettieri J, Liu R, Peña C, Berse M.

Thyroid. 2017 Sep;27(9):1118-1127. doi: 10.1089/thy.2017.0085. Epub 2017 Aug 29.

6.

A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.

Jones RL, Bendell JC, Smith DC, Diefenbach K, Lettieri J, Boix O, Lockhart AC, O'Bryant C, Moore KN.

Cancer Chemother Pharmacol. 2015 Oct;76(4):777-84. doi: 10.1007/s00280-015-2827-3. Epub 2015 Aug 18.

PMID:
26281907
7.

Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.

Hellmann MD, Sturm I, Trnkova ZJ, Lettieri J, Diefenbach K, Rizvi NA, Gettinger SN.

Clin Lung Cancer. 2015 Nov;16(6):514-22. doi: 10.1016/j.cllc.2015.04.003. Epub 2015 Apr 20.

8.

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.

Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, Köhne CH, Kornacker M, Boix O, Lettieri J, Krauss J, Fischer R, Hamann S, Strumberg D, Mross KB.

Ann Oncol. 2013 Jun;24(6):1560-7. doi: 10.1093/annonc/mdt056. Epub 2013 Mar 13.

9.

A case of bilateral lower cranial nerve palsies after base of skull trauma with complex management issues: case report and review of the literature.

Lehn AC, Lettieri J, Grimley R.

Neurologist. 2012 May;18(3):152-4. doi: 10.1097/NRL.0b013e318247bb6f. Review.

PMID:
22549358
10.

A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.

Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, Camidge DR.

J Thorac Oncol. 2012 Feb;7(2):419-26. doi: 10.1097/JTO.0b013e31823c5b11.

11.

Giant piezoelectricity on Si for hyperactive MEMS.

Baek SH, Park J, Kim DM, Aksyuk VA, Das RR, Bu SD, Felker DA, Lettieri J, Vaithyanathan V, Bharadwaja SS, Bassiri-Gharb N, Chen YB, Sun HP, Folkman CM, Jang HW, Kreft DJ, Streiffer SK, Ramesh R, Pan XQ, Trolier-McKinstry S, Schlom DG, Rzchowski MS, Blick RH, Eom CB.

Science. 2011 Nov 18;334(6058):958-61. doi: 10.1126/science.1207186.

12.

Assessment of the effects of renal impairment on the pharmacokinetics of the soluble guanylate cyclase activator cinaciguat after a single intravenous dose.

Lettieri JT, Scheerans C, Blunck M, Mazzu AL, Frey R, Mück W, Sundaresan PR.

J Clin Pharmacol. 2012 Aug;52(8):1240-7. doi: 10.1177/0091270011410567. Epub 2011 Aug 25.

PMID:
21868716
13.

Skin sparing mastectomy with delayed implant reconstruction.

Hird RB, Rousseau J, Nguyen C, Lettieri J, Orr RK.

Am Surg. 2010 Jul;76(7):785-7. No abstract available.

PMID:
20698397
14.
15.

Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics.

Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P.

Cancer Chemother Pharmacol. 2006 May;57(5):685-92. Epub 2005 Aug 25.

PMID:
16133532
16.

In situ epitaxial MgB2 thin films for superconducting electronics.

Zeng X, Pogrebnyakov AV, Kotcharov A, Jones JE, Xi XX, Lysczek EM, Redwing JM, Xu S, Li Q, Lettieri J, Schlom DG, Tian W, Pan X, Liu ZK.

Nat Mater. 2002 Sep;1(1):35-8.

PMID:
12618845
17.

Optimizing wound healing in the face after laser abrasion.

Goldman MP, Roberts TL 3rd, Skover G, Lettieri JT, Fitzpatrick RE.

J Am Acad Dermatol. 2002 Mar;46(3):399-407.

PMID:
11862176
18.

Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers.

Lettieri J, Vargas R, Agarwal V, Liu P.

Clin Pharmacokinet. 2001;40 Suppl 1:19-25.

PMID:
11352438
19.

The influence of age and gender on the pharmacokinetics of moxifloxacin.

Sullivan JT, Lettieri JT, Liu P, Heller AH.

Clin Pharmacokinet. 2001;40 Suppl 1:11-8.

PMID:
11352437
20.

Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults.

Isaacsohn J, Zinny M, Mazzu A, Lettieri J, Heller AH.

Eur J Clin Pharmacol. 2001 Mar;56(12):897-903.

PMID:
11317478
21.

Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.

Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P.

Clin Pharmacol Ther. 2000 Oct;68(4):391-400.

PMID:
11061579
22.

Influence of renal function on the pharmacokinetics of cerivastatin in normocholesterolemic adults.

Mazzu AL, Lettieri JT, Kelly E, Vargas R, Marbury T, Liu MC, Sundaresan P.

Eur J Clin Pharmacol. 2000 Apr;56(1):69-74.

PMID:
10853881
23.

Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone.

Sullivan JT, Woodruff M, Lettieri J, Agarwal V, Krol GJ, Leese PT, Watson S, Heller AH.

Antimicrob Agents Chemother. 1999 Nov;43(11):2793-7.

24.
25.

Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.

Mück W, Ochmann K, Mazzu A, Lettieri J.

J Int Med Res. 1999 May-Jun;27(3):107-14.

PMID:
10505300
26.

Absolute bioavailability of moxifloxacin.

Ballow C, Lettieri J, Agarwal V, Liu P, Stass H, Sullivan JT.

Clin Ther. 1999 Mar;21(3):513-22.

PMID:
10321420
27.
28.

Effects of beano on the tolerability and pharmacodynamics of acarbose.

Lettieri JT, Dain B.

Clin Ther. 1998 May-Jun;20(3):497-504.

PMID:
9663365
29.

Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease.

Pettigrew LC, Bieber F, Lettieri J, Wermeling DP, Schmitt FA, Tikhtman AJ, Ashford JW, Smith CD, Wekstein DR, Markesbery WR, Orazem J, Ruzicka BB, Mas J, Gulanski B.

J Clin Pharmacol. 1998 Mar;38(3):236-45.

PMID:
9549662
30.

Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.

Rubio TT, Miles MV, Lettieri JT, Kuhn RJ, Echols RM, Church DA.

Pediatr Infect Dis J. 1997 Jan;16(1):112-7; discussion 123-6.

PMID:
9002120
31.

Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.

Shah A, Lettieri J, Blum R, Millikin S, Sica D, Heller AH.

J Antimicrob Chemother. 1996 Jul;38(1):103-16.

PMID:
8858462
32.

Ciprofloxacin pharmacokinetics in burn patients.

Garrelts JC, Jost G, Kowalsky SF, Krol GJ, Lettieri JT.

Antimicrob Agents Chemother. 1996 May;40(5):1153-6.

33.

Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin.

Israel DS, Stotka J, Rock W, Sintek CD, Kamada AK, Klein C, Swaim WR, Pluhar RE, Toscano JP, Lettieri JT, Heller AH, Polk RE.

Clin Infect Dis. 1996 Feb;22(2):251-6.

PMID:
8838180
34.

Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects.

Shah A, Lettieri J, Nix D, Wilton J, Heller AH.

Antimicrob Agents Chemother. 1995 Apr;39(4):1003-6.

35.

Pharmacokinetics of Nisoldipine Coat--Core Formulation in Subjects with Liver Cirrhosis.

Shah A, Krol G, Sundaresan P, Lettieri J, Falk R, Lasseter K, Heller AH.

Am J Ther. 1995 Jan;2(1):15-19.

PMID:
11850642
36.

Safety and tolerance of intravenous nimodipine.

Sramek JJ, Heller AH, Sundaresan PR, Lettieri J, Sawin S, Cutler NR.

Ann Pharmacother. 1994 Oct;28(10):1143-8.

PMID:
7841566
37.

Comparative pharmacokinetics and safety of ciprofloxacin 400 mg i.v. thrice daily versus 750 mg po twice daily.

Shah A, Lettieri J, Kaiser L, Echols R, Heller AH.

J Antimicrob Chemother. 1994 Apr;33(4):795-801.

PMID:
8056698
38.

LC separation and induced fluorometric detection of rivastatin in blood plasma.

Krol GJ, Beck GW, Ritter W, Lettieri JT.

J Pharm Biomed Anal. 1993 Nov-Dec;11(11-12):1269-75.

PMID:
8123743
39.

Effects of cardiopulmonary bypass surgery on intravenous ciprofloxacin disposition.

Pryka RD, Rodvold KA, Ting W, Levitsky S, Frost RW, Lettieri JT.

Antimicrob Agents Chemother. 1993 Oct;37(10):2106-11.

40.

Multiple dose pharmacokinetics of four different doses of nisoldipine in hypertensive patients.

Chandler MH, Clifton GD, Lettieri JT, Mazzu AL, Allington DR, Thieneman AC, Foster TS, Harrison MR.

J Clin Pharmacol. 1992 Jun;32(6):571-5.

PMID:
1634646
41.

Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses.

Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH.

Antimicrob Agents Chemother. 1992 May;36(5):993-6.

42.

Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.

Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT.

Antimicrob Agents Chemother. 1992 Apr;36(4):830-2.

43.

Craniofacial suture stenosis: morphologic effects.

Persing JA, Lettieri JT, Cronin AJ, Wolcott WP, Singh V, Morgan E.

Plast Reconstr Surg. 1991 Oct;88(4):563-71; discussion 572-3.

PMID:
1896528
44.

Lidocaine diffusion in five tissue expanders: an in vitro and in vivo study.

Berman DE, Lettieri J, Herold DA, Thorne J, Morgan RF.

Ann Plast Surg. 1991 Oct;27(4):312-5.

PMID:
1772222
45.

Steroid and benzyl alcohol diffusion through tissue expanders and double lumen breast implants.

Berman DE, Lettieri J, Herold DA, Lin YF, Morgan RF.

Ann Plast Surg. 1991 Oct;27(4):316-20.

PMID:
1663323
46.

Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.

Nix DE, Watson WA, Lener ME, Frost RW, Krol G, Goldstein H, Lettieri J, Schentag JJ.

Clin Pharmacol Ther. 1989 Dec;46(6):700-5.

PMID:
2598571
47.

Lidocaine permeability in silicone tissue expanders: an in vitro analysis.

Berman DE, Lettieri J, Herold D, Edlich RF, Morgan RF.

Plast Reconstr Surg. 1989 Oct;84(4):621-3.

PMID:
2780903
48.

Ciprofloxacin pharmacokinetics after a standard or high-fat/high-calcium breakfast.

Frost RW, Carlson JD, Dietz AJ Jr, Heyd A, Lettieri JT.

J Clin Pharmacol. 1989 Oct;29(10):953-5. No abstract available.

PMID:
2592586
49.

Effect of quinolone antimicrobials on theophylline pharmacokinetics.

Prince RA, Casabar E, Adair CG, Wexler DB, Lettieri J, Kasik JE.

J Clin Pharmacol. 1989 Jul;29(7):650-4.

PMID:
2760258
50.

Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding.

Yuk JH, Nightingale CH, Sweeney KR, Quintiliani R, Lettieri JT, Frost RW.

Antimicrob Agents Chemother. 1989 Jul;33(7):1118-20.

Supplemental Content

Loading ...
Support Center